Novo Nordisk’s Wegovy Secures Landmark Accelerated USFDA Approval for MASH, Positioning It as First GLP-1 Therapy for Liver Disease

Novo Nordisk has received final approval from the U.S. Food and Drug Administration (FDA) for a new indication for its blockbuster drug, Wegovy (semaglutide) injection. The approval, granted under the accelerated pathway, is for the treatment of metabolic-associated steatohepatitis (MASH) in adults who have moderate-to-advanced liver fibrosis (scarring), but not cirrhosis. This makes Wegovy the first and only GLP-1 receptor agonist approved for this serious liver condition.

MASH, a progressive form of metabolic-associated fatty liver disease, is a significant and growing public health concern. It is characterized by the buildup of fat in the liver, leading to inflammation and scarring (fibrosis). If left untreated, MASH can progress to severe conditions such as cirrhosis, liver failure, and liver cancer, making it a leading cause of liver transplants. The condition is closely linked to obesity, type 2 diabetes, and high cholesterol.

Clinical Data Supporting the Approval

The FDA’s decision was based on the positive interim results from Part 1 of the ongoing Phase 3 ESSENCE trial. At the 72-week mark, a planned interim analysis of 800 participants showed compelling results for Wegovy compared to a placebo, with both groups also following lifestyle modifications.

MASH Resolution: 63% of participants receiving Wegovy achieved MASH resolution with no worsening of liver scarring, compared to 34% in the placebo group.
Fibrosis Improvement: 37% of participants on Wegovy showed improvement in liver scarring with no worsening of MASH, compared to 22% in the placebo group.

The trial is designed to continue for a total of 240 weeks. The second part of the study aims to confirm whether the histological improvements observed after 72 weeks translate into a reduction in clinically meaningful events, such as liver-related death or the need for a liver transplant.

Strategic Implications and Market Outlook

This approval is a major strategic victory for Novo Nordisk. With its established success in treating obesity and cardiovascular events, Wegovy is now uniquely positioned to address a new and rapidly expanding patient population. MASH is estimated to affect approximately 14.9 million adults in the U.S., and its prevalence is projected to grow.

The approval also positions Wegovy as a direct competitor to Rezdiffra (resmetirom), the first-ever MASH-specific drug, which received accelerated approval from the FDA in March 2024. Analysts suggest that the MASH market is large enough for multiple players, and that a drug with proven benefits for both liver disease and associated metabolic conditions like obesity and diabetes could become a “backbone treatment” for MASH. The news of the approval caused Novo Nordisk’s stock to rise, reflecting investor confidence in the drug’s new market potential.

Wegovy was granted Breakthrough Therapy designation for this indication, which expedited its development and review, highlighting the significant unmet medical need for MASH treatments.